Download
fphar-12-709467.pdf 1,89MB
WeightNameValue
1000 Titel
  • Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake
1000 Autor/in
  1. Sainsily, Xavier |
  2. Coquerel, David |
  3. Giguère, Hugo |
  4. Dumont, Lauralyne |
  5. Tran, Kien |
  6. Noll, Christophe |
  7. Ionescu, Andrei L. |
  8. Côté, Jérôme |
  9. Longpré, Jean-Michel |
  10. Carpentier, André |
  11. Marsault, Éric |
  12. Lesur, Olivier |
  13. Sarret, Philippe |
  14. Auger-Messier, Mannix |
1000 Verlag
  • Frontiers Media S.A.
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-27
1000 Erschienen in
1000 Quellenangabe
  • 12:709467
1000 Copyrightjahr
  • 2021
1000 Embargo
  • 2022-01-29
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fphar.2021.709467 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353398/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Abstract/Summary
  • <jats:p><jats:bold>Objectives:</jats:bold> Arterial hypertension, when exacerbated by excessive dietary salt intake, worsens the morbidity and mortality rates associated with cardiovascular and renal diseases. Stimulation of the apelinergic system appears to protect against several circulatory system diseases, but it remains unknown if such beneficial effects are conserved in severe hypertension. Therefore, we aimed at determining whether continuous infusion of apelinergic ligands (i.e., Apelin-13 and Elabela) exerted cardiorenal protective effects in spontaneously hypertensive (SHR) rats receiving high-salt diet.</jats:p><jats:p><jats:bold>Methods:</jats:bold> A combination of echocardiography, binding assay, histology, and biochemical approaches were used to investigate the cardiovascular and renal effects of Apelin-13 or Elabela infusion over 6 weeks in SHR fed with normal-salt or high-salt chow.</jats:p><jats:p><jats:bold>Results:</jats:bold> High-salt intake upregulated the cardiac and renal expression of APJ receptor in SHR. Importantly, Elabela was more effective than Apelin-13 in reducing high blood pressure, cardiovascular and renal dysfunctions, fibrosis and hypertrophy in high-salt fed SHR. Unlike Apelin-13, the beneficial effects of Elabela were associated with a counter-regulatory role of the ACE/ACE2/neprilysin axis of the renin-angiotensin-aldosterone system (RAAS) in heart and kidneys of salt-loaded SHR. Interestingly, Elabela also displayed higher affinity for APJ in the presence of high salt concentration and better resistance to RAAS enzymes known to cleave Apelin-13.</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> These findings highlight the protective action of the apelinergic system against salt-induced severe hypertension and cardiorenal failure. As compared with Apelin-13, Elabela displays superior pharmacodynamic and pharmacokinetic properties that warrant further investigation of its therapeutic use in cardiovascular and kidney diseases.</jats:p>
1000 Sacherschließung
lokal Pharmacology
lokal ACE2
lokal sodium diet
lokal renin–angiotensin–aldosterone system
lokal Apelin
lokal neprilysin
lokal hypertension
lokal APJ receptor
lokal Elabela/Toddler
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2FpbnNpbHksIFhhdmllcg==|https://frl.publisso.de/adhoc/uri/Q29xdWVyZWwsIERhdmlk|https://frl.publisso.de/adhoc/uri/R2lndcOocmUsIEh1Z28=|https://frl.publisso.de/adhoc/uri/RHVtb250LCBMYXVyYWx5bmU=|https://frl.publisso.de/adhoc/uri/VHJhbiwgS2llbg==|https://frl.publisso.de/adhoc/uri/Tm9sbCwgQ2hyaXN0b3BoZQ==|https://frl.publisso.de/adhoc/uri/SW9uZXNjdSwgQW5kcmVpIEwu|https://frl.publisso.de/adhoc/uri/Q8O0dMOpLCBKw6lyw7RtZQ==|https://frl.publisso.de/adhoc/uri/TG9uZ3Byw6ksIEplYW4tTWljaGVs|https://frl.publisso.de/adhoc/uri/Q2FycGVudGllciwgQW5kcsOp|https://frl.publisso.de/adhoc/uri/TWFyc2F1bHQsIMOJcmlj|https://frl.publisso.de/adhoc/uri/TGVzdXIsIE9saXZpZXI=|https://frl.publisso.de/adhoc/uri/U2FycmV0LCBQaGlsaXBwZQ==|https://frl.publisso.de/adhoc/uri/QXVnZXItTWVzc2llciwgTWFubml4
1000 Hinweis
  • DeepGreen-ID: aef73606c60d4d9d95e5d4f5343fe7b2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Canadian Institutes of Health Research |
  2. Fonds de Recherche du Québec - Santé |
  3. Heart and Stroke Foundation of Canada |
  4. Canada Research Chairs |
1000 Fördernummer
  1. -
  2. -
  3. -
  4. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Canadian Institutes of Health Research |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Fonds de Recherche du Québec - Santé |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Heart and Stroke Foundation of Canada |
    1000 Förderprogramm -
    1000 Fördernummer -
  4. 1000 joinedFunding-child
    1000 Förderer Canada Research Chairs |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6476987.rdf
1000 Erstellt am 2024-05-17T10:28:36.734+0200
1000 Erstellt von 322
1000 beschreibt frl:6476987
1000 Zuletzt bearbeitet 2024-05-17T14:00:51.972+0200
1000 Objekt bearb. Fri May 17 14:00:51 CEST 2024
1000 Vgl. frl:6476987
1000 Oai Id
  1. oai:frl.publisso.de:frl:6476987 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source